Professor Ekaterine Berishvili-Berns co-authored a research paper published in a reputed journal Nature Communication
A research article Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes co-authored by Professor Ekaterine Berishvili-Berns, a faculty member of the ISU Medical School, was published in a reputed journal Nature Communication.
Intraportal transplantation of pancreatic islets, also called islets of Langerhans, is an established therapy for patients with severe type 1 diabetes. Sometimes, the method is even thought to be the last resort to save the patient’s life. Despite the positive outcomes, clinical transplantation of islets of Langerhans requires further improvements. The main challenges of cell-based therapy are: the inflammatory response, delayed vascularization and most importantly, the need for lifelong immunosuppression. Therefore, the method is used restrictively, only in patients with severe diabetes. Together with their colleagues from Geneva, ISU researchers have developed an original method to address the challenges. Pancreatic islets and amniotic epithelial cells were used to engineer insulin-producing organoids that demonstrate greater stability than islets. The experiments and observations confirmed that the so-called super-pancreatic islets are characterized by better integration into the microenvironment and therefore, demonstrate higher functionality resulting in prompt normalization of blood glucose levels.
Lebreton, F., Lavallard, V., Bellofatto, K. Bonnet R, Wassmer C.H, Perez L, Kalandadze V, Follenzi A, Boulvain M, Kerr-Conte J, David J. Goodman D.J, Domenico Bosco D, Berney T & Brishvili E,Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes. Nat Commun 10, 4491 (2019). https://doi.org/10.1038/s41467-019-12472-3